Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Growth 2024-2030

Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Growth 2024-2030

Dipeptide Peptidase 4 (DPP-4) Inhibitors are a class of oral diabetes drugs that work by blocking the action of DPP-4, an enzyme which destroys a group of gastrointestinal hormones called incretins. Incretins help stimulate the production of insulin when it is needed (e.g. after eating) and reduce the production of glucagon by the liver when it is not needed (e.g. during digestion). They also slow down digestion and decrease appetite. So by protecting incretins from damage, DPP-4 inhibitors help regulate blood glucose levels.

The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market size is projected to grow from US$ 8788.8 million in 2023 to US$ 10370 million in 2030; it is expected to grow at a CAGR of 2.4% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Forecast” looks at past sales and reviews total world Dipeptide Peptidase 4 (DPP-4) Inhibitors sales in 2023, providing a comprehensive analysis by region and market sector of projected Dipeptide Peptidase 4 (DPP-4) Inhibitors sales for 2024 through 2030. With Dipeptide Peptidase 4 (DPP-4) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Dipeptide Peptidase 4 (DPP-4) Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Dipeptide Peptidase 4 (DPP-4) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Dipeptide Peptidase 4 (DPP-4) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Dipeptide Peptidase 4 (DPP-4) Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Dipeptide Peptidase 4 (DPP-4) Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Dipeptide Peptidase 4 (DPP-4) Inhibitors.

Januvia (Sitagliptin), Galvus (Vildagliptin), Onglyza (Saxagliptin), Tradjenta (Linagliptin) are the major DPP-4 drugs in the market.

This report presents a comprehensive overview, market shares, and growth opportunities of Dipeptide Peptidase 4 (DPP-4) Inhibitors market by product type, application, key manufacturers and key regions and countries.

Segmentation by type
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
Vildagliptin

Segmentation by application
Hospitals
Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Merck
Eli Lilly
AstraZenica
Boehringer Ingelheim
Takeda Pharmaceutical Company
BMS

Key Questions Addressed in this Report

What is the 10-year outlook for the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market?

What factors are driving Dipeptide Peptidase 4 (DPP-4) Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Dipeptide Peptidase 4 (DPP-4) Inhibitors market opportunities vary by end market size?

How does Dipeptide Peptidase 4 (DPP-4) Inhibitors break out type, application?

Please note: The report will take approximately 2 business days to prepare and deliver.